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Collectins are multimeric host defence lectins with trimeric CRDs
(carbohydrate-recognition domains) and collagen and N-terminal
domains that form higher-order structures composed of four or
more trimers. Recombinant trimers composed of only the CRD
and adjacent neck domain (termed NCRD) retain binding activity
for some ligands and mediate some functional activities. The
lung collectin SP-D (surfactant protein D) has strong neutralizing
activity for IAVs (influenza A viruses) in vitro and in vivo,
however, the NCRD derived from SP-D has weak viral-binding
ability and lacks neutralizing activity. Using a panel of mAbs
(monoclonal antibodies) directed against the NCRD in the present
study we show that mAbs binding near the lectin site inhibit
antiviral activity of full-length SP-D, but mAbs which bind
other sites on the CRD do not. Two of the non-blocking mAbs
significantly increased binding and antiviral activity of NCRDs as
assessed by haemagglutination and neuraminidase inhibition and
by viral neutralization. mAb-mediated cross-linking also enabled
NCRDs to induce viral aggregation and to increase viral uptake
by neutrophils and virus-induced respiratory burst responses by
these cells. These results show that antiviral activities of SP-D
can be reproduced without the N-terminal and collagen domains
and that cross-linking of NCRDs is essential for antiviral activity
of SP-D with respect to IAV.
Key words: collectin, influenza A virus, lectin, neutrophil,
surfactant protein D.
INTRODUCTION
SP-D (surfactant protein D) plays important roles in innate de-
fence against IAV (influenza A virus) and other viral and bacterial
infections [1–6]. Trimeric NCRD [neck plus CRD (carbohydrate-
recognition domain)] fragments of human or rodent SP-D
are functional lectins and efficiently bind to some microbial
ligands including mannan and bacterial lipopolysaccharides [7].
Furthermore, NCRD preparations have been found to bind to
correct many abnormalities of SP-D−/− mice [8–11]. These
findings have raised hope that NCRDs may be employed as
therapy for some infectious or inflammatory states. Unfortunately,
the isolated trimeric NCRD of human SP-D binds weakly
to IAV and does not inhibit viral infectivity, despite strong
binding and neutralizing activity for full-length SP-D dodecamers
[12,13]. hNCRDs (human NCRDs) and trimers also bind poorly
to phosphatidylinositol, as compared with human dodecamers
[7]. Overall, these results suggest that wild-type SP-D has a
remarkable dependence on co-operativity among NCRDs for
binding to some ligands (e.g. IAV and phosphatidylinositol). Of
interest, replacement of key residues around the lectin-binding
site of SP-D results in the ability of some mutant NCRDs to
efficiently bind to and neutralize IAV.
In the process of studying the epitopes and functional effects
of mAbs (monoclonal antibodies) directed against the NCRD
of human SP-D, we found that certain antibodies blocked the
antiviral activity of wild-type SP-D, whereas others did not.
Furthermore, among the non-blocking mAbs, we found that two
mAbs increased viral binding and antiviral activity of hNCRDs.
This provided us with a useful model system for testing the role
of binding co-operativity in the antiviral activity of SP-D.
MATERIALS AND METHODS
Buffers and reagents
Dulbecco’s PBS containing 0.9 mM calcium and 0.493 mM
magnesium and PBS without calcium and magnesium were
purchased from Invitrogen. PBS with added calcium and
magnesium at pH 7.2 was used unless otherwise indicated.
SP-D preparation
The SP-D preparations used in the present study are summarized
in Table 1. The methods for preparation of most of these
constructs have been described previously. Dodecamers of wild-
type recombinant human or rat SP-Ds were used as control
preparations and were expressed in CHO (Chinese-hamster ovary)
cells and purified as described in [14]. NCRD preparations,
including the RAK (hNCRD with the insertion of arginine,
alanine and lysine between residues 324 and 325) and E321K
mutants, were produced in Escherichia coli as described [12,13].
A neckless mutant 9 [hCRD (human CRD)] that cannot form
trimers, was isolated and characterized as previously described
[15]. In the E321K mutant the glutamine residue at position 321
was replaced with lysine by site-directed mutagenesis.
Monoclonal antibodies
mAbs 245-01, 245-02 and 246-02–246–08 were raised against SP-
D by inoculating mice with 10 μg/ml human SP-D as previously
described [16]. The 245-01 antibody, which was raised against a
recombinant fragment of human SP-D composed of only the neck
and CRD, recognizes human SP-D by Western blot analysis in the
reduced and unreduced form, and was shown to be effective for
Abbreviations used: CRD, carbohydrate-recognition domain; EM, electron microscopy; HA, haemagglutinin; IAV, influenza A virus; mAb, monoclonal
antibody; MDCK, Madin–Darby canine kidney; NCRD, neck plus CRD; SP-D, surfactant protein D.
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Table 1 Recombinant collectins used in the present study
Collectin Properties
Human SP-D Full-length dodecamers
hNCRD Trimer containing only the neck and CRD of wild-type human SP-D
rNCRD and Like hNCRD but using sequences of rat (r) or mouse (m) SP-D
mNCRD
RAK hNCRD with the insertion of arginine, alanine and lysine between residues
hCRD Like hNCRD but lacking the neck region
E321K Substitutes lysine for one of the primary calcium-binding amino acids
immunolocalization of SP-D in human tissues. The 246-07 mAb
probably binds to the primary calcium and saccharide-binding
region of the CRD because it blocks binding of SP-D to mannan
[17]. In contrast, the 246-04 mAb binds to a distinct region of the
CRD and does not block binding to mannan. The 246-04 mAb
does, however, block binding of human SP-D to lung gp-340, a
secreted member of the scavenger receptor superfamily that can
co-isolate with SP-D [17].
Binding of mAbs to SP-D (wild-type and mutants)
SP-D preparations were diluted in coating buffer [15 mM Na2CO3
and 35 mM NaHCO3, (pH 9.6)] to a concentration of 2 μg/ml
and coated on to ELISA plates overnight, followed by washing
and addition of mAbs. The final concentration of mAbs used for
the ELISA assay was 1 μg/ml. Bound mAbs were detected with
HRP (horseradish peroxidase)-conjugated donkey anti-mouse
antibodies followed by TMB (3,3′,5,5′-tetramethylbenzidene)
peroxidase. A450 values were measured on a POLARstar OPTIMA
plate reader (BMG Labtech).
Virus preparations
IAV was grown in the chorioallantoic fluid of 10-day-old
chicken eggs and purified on a discontinuous sucrose gradient
as previously described [18]. The virus was dialysed against PBS
to remove sucrose, aliquoted and stored at −80 ◦C until needed.
Philippines 82/H3N2 (Phil82) strain was kindly provided by Dr
E. Margot Anders (Department of Microbiology, University of
Melbourne, Melbourne, Australia). Post-thawing, the viral stocks
contained ∼5 × 108 plaque-forming units/ml.
HA (haemagglutinin) inhibition assay
HA inhibition was measured by serially diluting collectin or
other host defence protein preparations in round-bottomed 96-
well plates (Serocluster U-Vinyl plates; Costar) using PBS as a
diluent. After adding 25 μl of IAV, giving a final concentration
of 40 HA units/ml or 4 HA units/well, the IAV–protein mixture
was incubated for 15 min at room temperature (25 ◦C), followed
by addition of 50 μl of a type O human erythrocyte suspension
(containing ∼108 erythrocytes/ml). The minimum concentration
of protein required to inhibit fully the haemagglutinating
activity of the viral suspension was determined by noting the
highest dilution of protein that still inhibited haemagglutination.
Inhibition of HA activity in a given well is demonstrated by the
absence of formation of an erythrocyte pellet. If no inhibition of
HA activity was observed at the highest protein concentration used
then the value is expressed as >the maximal protein concentration.
Measurement of viral aggregation by collectins
Viral aggregation was measured by light transmission and EM
(electron microscopy) as previously described [19].
Fluorescent focus assay of IAV infectivity
MDCK (Madin–Darby canine kidney) cell monolayers were
prepared in 96-well plates and grown to confluency. These layers
were then infected with diluted IAV preparations for 45 min at
37 ◦C in PBS and tested for the presence of IAV-infected cells after
7 h using a monoclonal antibody directed against the influenza A
viral nucleoprotein (provided by Dr Nancy Cox, CDC, Atlanta,
GA, U.S.A.) as previously described [20]. IAV was pre-incubated
for 30 min at 37 ◦C with SP-D or control buffer (PBS), followed
by addition of these viral samples to the MDCK cells. Where
indicated, SP-Ds were first incubated with mAbs prior to adding
them to IAV.
Human neutrophil preparation
Neutrophils from healthy volunteers were isolated to >95%
purity using dextran precipitation, followed by Ficoll–Paque
gradient separation for the removal of mononuclear cells, and
then hypotonic lysis to eliminate any contaminating erythrocytes,
as previously described [18]. Cell viability was determined to be
>98% by Trypan Blue staining. The isolated neutrophils were
resuspended at the appropriate concentrations in control buffer
(PBS) and used within 2 h. Neutrophil collection was performed
with informed consent as approved by the Institutional Review
Board of Boston University School of Medicine, Boston, MA,
U.S.A.
Measurement of IAV uptake by neutrophils
FITC-labelled IAV (Phil82 strain) was prepared and the uptake
of the virus by neutrophils was measured as previously described
[21]. In brief, IAV was incubated with neutrophils for 30 min
at 37 ◦C in the presence of control buffer. Trypan Blue
(0.2 mg/ml) was added to these samples to quench extracellular
fluorescence. Following washing, the neutrophils were fixed with
paraformaldehyde and neutrophil-associated fluorescence was
measured using flow cytometry. The mean neutrophil fluorescence
(>1000 cells counted per sample) was measured.
Measurement of neutrophil H2O2 production
H2O2 production was measured by assessing the reduction in
scopoletin fluorescence as previously described [22]. Measure-
ments were made using the plate reader as described above.
Statistics
Statistical comparisons were made using Student’s paired, two-
tailed t test or ANOVA with post-hoc test (Tukey’s). ANOVA was
used for multiple comparisons with a single control.
RESULTS
Interactions of mAbs with SP-D
We compared binding of a panel of mAbs raised against human
SP-D with full-length human SP-D and NCRDs derived from
rat and mouse SP-D (Figure 1). Note that some epitopes were
conserved between human and rodent SP-Ds (e.g. 246-03);
whereas other epitopes were partially retained in rat SP-D but
not mouse SP-D (246-04 and 246-08). In Figure 2 (left-hand
panel) we next compared binding of mAbs with hNCRD or hCRD
(which differ in that the latter lacks the neck domain). All mAbs
bound to the hNCRD trimer preparation. mAb 245-01 did not
bind to hCRD, strongly suggesting that this mAb recognizes
the neck region of SP-D. Because 245-01 had reduced binding
to full-length SP-D (Figure 1) the epitope that it recognizes
may be less accessible in the full-length molecule than in the
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 1 Binding of mAbs to human SP-Ds or rat or mouse NCRDs
Binding of mAbs to human SP-D dodecamers or NCRD preparations of rat or mouse SP-D were
assessed by ELISA. Results are means +− S.E.M. of four experiments.
NCRD. Monoclonal 245-02 may bind to the junction of the
neck and CRD because binding was greatly, but not completely,
reduced to hCRD. Of interest, binding of 246-07 was also greatly
reduced in hCRD. We have previously reported that this mAb
blocks antiviral activity of SP-D and binding to mannan and
very probably recognizes an epitope near or overlapping the
carbohydrate-binding site [23,24].
We also compared binding of the mAbs with two mutant
versions of hNCRD, RAK and E321K (Figure 2, right-hand
panel). The RAK mutant has a three-amino-acid insertion adjacent
to Asp325 and slightly increased antiviral activity compared with
wild-type hNCRD [13]. Asp325 is found on the N-terminal ridge
adjoining the primary calcium and saccharide-binding site and
the interspecies substitution of asparagine at position 325 was
shown to alter the affinity for ManNAc. The mAbs 246-02, 246-
03, 246-05 and 246-07 had reduced binding to RAK (Figure 2,
right-hand panel); hence, it is likely that the epitopes recognized
by the mAbs overlap with the saccharide-binding site. Binding of
mAbs 245-01, 245-02, 246-04 and 246-08 was not reduced by the
RAK insertion implying that they do not bind near Asp325. Glu321 is
one of the amino acids that co-ordinates with the primary calcium
and replacement of this residue with a lysine residue results in
loss of lectin activity. As shown in Figure 2 (right-hand panel)
mAbs 246-03, 246-05 and 246-07 had greatly reduced binding
to E321K again indicating that these mAbs recognize epitopes
overlapping the saccharide-binding site of the CRD. Binding of
mAb 246-06 was also reduced to some extent in both RAK and
E321K mutants.
In Figure 3 we show that 246-07 and three other mAbs (246-02,
246-03 and 246-05) strongly inhibited binding of full-length SP-
D to IAV. In contrast, mAbs 246-04 and 246-08 caused minimal
inhibition of binding to IAV, and 246-06 had an intermediate
effect. As shown in Table 2 (first column of results), the 246-
02, 246-03 and 246-05 mAbs also interfered with HA inhibitory
activity of SP-D; whereas 245-01, 245-02, 246-04, 246-06 and
246-08 did not. These results support the concept that the former
antibodies bind near the saccharide-binding site, whereas the latter
do not.
Effects of non-inhibitory mAbs on HA-inhibiting and neutralizing
activity of NCRDs for IAV
The ability of SP-D to neutralize or inhibit HA activity of IAV
has been shown to depend on binding to glycans on the HA of
the virus [20]. Wild-type hNCRD has minimal binding to IAV
using ELISA assays and does not cause any inhibition of HA
activity or infectivity [6]. As shown in Table 2 (middle column
of results), addition of either 246-04 or 246-08 mAb enabled
hNCRD to inhibit HA activity of IAV. The 246-08 was somewhat
more potent than 246-04 at enhancing the HA-inhibitory activity
of hNCRD. The E321K mutant lacked HA-inhibitory activity and
this was not altered by the 246-08 mAb (Table 2, last column).
As shown in Figure 4, mAbs 246-04 and 246-08 enabled
hNCRD to mediate viral-neutralizing activity. Although hNCRD
Figure 2 Binding of mAbs to hNCRD, hCRD or RAK or E321K mutant NCRDs
Binding was tested by ELISA as in Figure 1. In the left-hand panel binding of mAbs to hNCRD was compared with binding to hCRD. mAbs 245-01, 245-02 and 246-07 bound significantly less to
hCRD (the preparation lacking the neck domain) than to hNCRD. The right-hand panel shows binding of mAbs to the RAK and E321K mutant versions of hNCRD. The mAbs 246-02, 246-03, 246-05,
246-06 and 246-07 bound significantly less to RAK than to hNCRD. mAbs 246-03, 246-05, 246-06 and 246-07 bound significantly less to E321K than to hNCRD.
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Figure 3 Effects of mAbs on binding of SP-D to IAV
In this assay IAV was coated on to the plate overnight and SP-D dodecamers were pre-incubated
with control buffer or the indicated mAbs (100 μg/ml during incubation with SP-D) prior to
testing the binding of SP-D to the virus. Results are means +− S.E.M. of three experiments.
mAbs 246-02, 246-03, 246-05 and 246-07 significantly reduced binding of SP-D to the virus
(P < 0.05), whereas 246-04, 246-06 and 246-08 did not. Results are expressed as a percentage
of control binding of SP-D.
Table 2 Effect of anti-SP-D mAbs on HA inhibition caused by SP-D
dodecamers, NCRD or E321K
The mAbs (1 μg/ml) were pre-incubated with SP-D (0.4 μg/ml) for 15 min at room temperature
(ratio 2.5:1 for mAb/SP-D); hNCRD (50 μg/ml) or E321K were pre-incubated in a similar manner
with mAbs (5 μg/ml) (ratio 1:10 for mAb/NCRD).
Minimal HA inhibiting concentration (μg/ml)
mAb SP-D dodecamers hNCRD (μg/ml) E321K
None 0.016 +− 0.008 >50 >50
245-01 0.014 +− 0.0007
245-02 0.015 +− 0.0008
246-02 >0.6*
246-03 0.15 +− 0.045*
246-04 0.017 +− 0.008 14 +− 1.2**
246-05 0.15 +− 0.036*
246-06 0.021 +− 0.001
246-08 0.016 +− 0.008 7.4 +− 0.9** >50
*Indicates significantly increased concentration of SP-D dodecamers needed to inhibit HA
activity in presence of mAbs 246-02, 246-03 and 246-05 (n = 9; P < 0.005).
**Indicates significantly reduced concentration of NCRD needed to inhibit HA activity in
presence of 246-04 or 246-08.
caused no viral aggregation as measured by light transmission
through a stirred viral suspension, addition of mAb 246-08
resulted in modest but statistically significant viral aggregation
as assessed by light transmission (Figure 5A) or EM (Figure 5B).
Effect of mAbs on the ability of NCRDs to inhibit viral
neuraminidase activity
Inhibition of neuraminidase activity of IAV appeared to be
strongly dependent on co-operative binding effects, and could
be largely mediated via steric effects following binding to the HA
[23]. hNCRD did not cause inhibition of neuraminidase activity
of IAV; however, inhibition was observed when hNCRD was
combined with mAb 246-04 or 246-08 (Figure 6).
Figure 4 MAbs 246-04 and 246-08 enable nNCRD to neutralize IAV
Viral neutralization by hNCRD was measured using the fluorescent focus assay on MDCK cells.
hNCRD alone did not cause any viral neutralization; however, when hNCRD was pre-incubated
with 4 μg/ml of 246-04 or 246-08 mAb significant neutralization was observed. mAbs alone
had no effect on the HA assay (results not shown).
Figure 5 MAb 246-08 allows hNCRD to induce viral aggregation
hNCRD (3.2 μg/ml) caused no viral aggregation on its own as assessed by light transmission
(A); however, it did so when pre-incubated with 2 μg/ml 246-08 mAb (P < 0.004 compared
with hNCRD alone). (B) shows aggregates as seen under EM. The control sample was incu-
bated with PBS with calcium and magnesium alone (no mAb or NCRD).
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Figure 6 mAbs enable hNCRD to inhibit viral neuraminidase activity
hNCRD alone caused no inhibition of neuraminidase (NA) activity, but did so when pre-incubated
with 5 μg/ml mAb 246-08 (n = 3; **P < 0.01 and *P < 0.03 when compared with hNCRD
alone).
Effect of mAbs on the ability of NCRDs to modify neutrophil
responses to IAV
IAV binds to and is ingested by neutrophils resulting in a
respiratory burst response characterized by H2O2 generation. Pre-
incubation of IAV with dodecamers of full-length SP-D markedly
potentiates viral uptake by neutrophils and virus-induced H2O2
generation [1,25]. These effects correlate in general with the
ability of SP-D to induce viral aggregation [26]. As expected,
hNCRD did not cause any increase in viral uptake or respiratory
burst responses by neutrophils; however, it did so when pre-
incubated with mAb 246-08 (Figures 7A and 7B).
DISCUSSION
SP-D plays an important role in the early innate defence against
common human strains of IAV. NCRD preparations of SP-D are
relatively easy to produce in large quantities and conveniently
assemble as trimers due to the coiled-coil structure of the neck
domain. NCRDs are being evaluated as possible therapeutics for
a variety of respiratory conditions in which natural functions
of SP-D are insufficient [8–10]. They also have the potential
advantage of lacking the collagen domain, which has been
implicated as a trigger for pro-inflammatory effects of SP-D
[27]. Unfortunately, NCRD preparations of wild-type SP-D have
a markedly diminished ability to bind to or inhibit IAV. Full-
length multimeric SP-D or a collagen domain mutant form of
SP-D, that retains the N-terminus and the ability to form small
multimers, both exhibit strong viral-neutralizing activity in vitro
and in vivo [28]. This implies that binding to IAV by SP-D is
strongly determined by co-operative interactions among CRD
heads. We have also reported that modifications of residues around
the lectin site of the hNCRD (e.g. as in the RAK mutant) can
confer viral binding and neutralizing activity [13].
In the present study we initially sought to characterize binding
of a panel of mAbs directed against the NCRD of human SP-
D to wild-type or mutant forms of SP-D. Although the mAbs
were generally highly specific for human SP-D, there was some
overlap in binding to rodent SP-Ds. Using the RAK-, E321K- and
hCRD-modified versions of hNCRD we provide partial mapping
of epitopes of some of the mAbs. mAbs 246-02, 246-03, 246-05
Figure 7 Effects of mAbs on the ability of hNCRD to increase neutrophil
uptake of IAV (A) or respiratory burst responses to IAV (B)
hNCRD did not increase neutrophil uptake of IAV on its own, but did so when it was pre-incubated
with 20 μg/ml mAb 246-08. (P < 0.05 for all comparisons by ANOVA; n = 4 using different
blood donors for each experiment). hNCRD (4 μg/ml) alone did not increase neutrophil H2O2
production in response to IAV (B), but pre-incubation with mAb 246-08 (5 μg/ml) did result in
H2O2 production (P < 0.05 compared with IAV alone or IAV with hNCRD as measured using
ANOVA). The mAb alone did not increase IAV-induced H2O2 production in the absence of NCRDs
(IAV + mAb 246-08). H2O2 production is expressed as a percentage of scopoletin fluorescence
at zero time.
and 246-07 bind near the lectin site of SP-D, whereas 245-01 and
245-02 bind to the neck region. Consistent with this interpretation,
mAbs 246-02, 246-03, 246-05 and 246-07 blocked binding of full-
length SP-D to IAV and interfered with HA inhibition caused by
full-length SP-D. The mAbs 245-01, 245-02, 246-04, 246-06 and
246-08 did not interfere with these activities of SP-D. Based on
moderately reduced binding to the RAK and E321K mutants, the
246-06 mAb may recognize a site which partially overlaps
the saccharide-binding site or binding surface of the CRD, but
it does not inhibit function.
Of interest, some of the non-blocking mAbs (246-04 and 246-
08) were found to increase viral binding and various antiviral
activities of hNCRD, including HA inhibition, virus neutralization
and neuraminidase inhibition. This was not a non-specific effect
of the mAbs, since cross-linking of E321K (which lacks lectin
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activity) did not result in antiviral activity. In addition the
mAbs enabled hNCRD to cause viral aggregation, supporting
the concept that the mAbs induced cross-linking of NCRDs. mAb
246-08 was more effective than 246-04 at enhancing antiviral
activities of hNCRD on several of the assays. mAb 246-04 likely
binds along the lateral surface of the CRD head. This conclusion
is based on the prior findings that porcine SP-D has a glycan in
this area which interferes with binding to lung gp-340 and mAb
246-04 blocks binding of gp-340 [17]. Of note, lung-derived gp-
340, like mAb 246-04, significantly potentiates antiviral activities
of SP-D. Further studies to more precisely determine the binding
sites of 246-04 and 246-08 are underway.
It is of interest that neither 245-01 nor 245-02 mAbs increased
activity of the NCRDs since Ohya et al. [15] have reported that
another mAb directed against the neck region of SP-D potentiated
binding to Toll-like receptors [15]. It is also notable that the mAbs
did not increase antiviral activities of full-length dodecameric
SP-D implying that co-operative binding is already maximal for
dodecameric SP-D.
The ability of the mAbs to enhance neutrophil responses to
IAV in the presence of the hNCRD will require further study.
We have previously shown that the ability of full-length SP-D
to induce viral aggregation correlates with its ability to promote
viral uptake by, and virus-induced respiratory burst responses of,
neutrophils [26,29]. Hence, the ability of hNCRD to aggregate
virus particles in the presence of mAb 246-08 may account
for the potentiation of neutrophil responses. It is also possible,
however, that the Fc domain of some murine mAbs can engage
neutrophil Fc receptors; future studies will involve preparation
of Fab1 and Fab2 fragments of anti-SP-D mAbs to evaluate this
possibility. Coupling of the SP-D NCRD to an Fab1 fragment of
an antibody-directed against CD89 (the Fc receptor for IgA on
neutrophils) results in dramatic increases in the uptake of IAV,
bacteria and Candida by neutrophils and an increase in
IAV-induced respiratory burst responses by these cells. Cross-
linking of NCRD with 246-04 or 246-08 mAbs could modulate
neutrophil responses in a similar manner [30].
Conclusions
We found that mAbs directed against the CRD of SP-D are
able to block or enhance antiviral activities of SP-D, consistent
with observed differences in the localization of their dominant
epitopes. The observation that incubation of hNCRD with the
non-blocking mAbs 246-04 and 246-08 allows hNCRD to
mediate viral aggregation and enhance neutralization provides
additional strong evidence that co-operative interactions between
NCRD trimers are important, if not critical, for anti-influenza
activity. The available results suggest that this is accomplished
by promoting cross-linking interactions between NCRD trimers,
thereby mimicking the normal multimeric structure of the native
collectin. Cross-linking of NCRDs with mAbs or through other
means may be a useful strategy in therapeutic applications of
collectins.
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